Close

More on ATNM

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (9.1 Score)
- Holders

Upcoming Events

- Earnings (5/13/24)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Actinium Pharma (NY:ATNM)
Delayed: 7.17 --0 (-0%)
Prev. Close $7.17  
Open$7.17 
52 Wk High$3.50 
52 Wk Low$0.86 
Day High$7.17 
Day Low$7.17 
P/E N/A  
EPS$-7.61 
Volume1,434 

Friends, Peers and Foes (?): NYSE, BLUE, AMGN, BIIB, IQV (more...)

Apr 18, 2024 08:08 AM Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
Apr 18, 2024 08:00 AM Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone
Apr 1, 2024 08:00 AM Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
Apr 1, 2024 08:00 AM Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Present
Mar 29, 2024 05:01 PM Form S-8 Actinium Pharmaceuticals
Mar 29, 2024 04:59 PM Form 10-K Actinium Pharmaceuticals For: Dec 31
Mar 26, 2024 07:18 AM Actinium Pharma (ATNM) Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Mar 26, 2024 07:18 AM Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Mar 11, 2024 07:32 AM Actinium Pharma (ATNM) Launches Actinium-225 Focused Strategic Initiative
Mar 11, 2024 07:30 AM Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
View All Articles

Entities mentioned with ATNM

View All Entities